IRIS Accounts Production v24.3.0.553 SC333815 Board of Directors 1.5.23 30.4.24 30.4.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC3338152023-04-30SC3338152024-04-30SC3338152023-05-012024-04-30SC3338152022-04-30SC3338152022-05-012023-04-30SC3338152023-04-30SC333815ns15:Scotland2023-05-012024-04-30SC333815ns14:PoundSterling2023-05-012024-04-30SC333815ns10:Director12023-05-012024-04-30SC333815ns10:PrivateLimitedCompanyLtd2023-05-012024-04-30SC333815ns10:SmallEntities2023-05-012024-04-30SC333815ns10:AuditExempt-NoAccountantsReport2023-05-012024-04-30SC333815ns10:SmallCompaniesRegimeForDirectorsReport2023-05-012024-04-30SC333815ns10:SmallCompaniesRegimeForAccounts2023-05-012024-04-30SC333815ns10:AbridgedAccounts2023-05-012024-04-30SC33381512023-05-012024-04-30SC333815ns10:Director22023-05-012024-04-30SC333815ns10:RegisteredOffice2023-05-012024-04-30SC333815ns5:CurrentFinancialInstruments2024-04-30SC333815ns5:CurrentFinancialInstruments2023-04-30SC333815ns5:Non-currentFinancialInstruments2024-04-30SC333815ns5:Non-currentFinancialInstruments2023-04-30SC333815ns5:ShareCapital2024-04-30SC333815ns5:ShareCapital2023-04-30SC333815ns5:RetainedEarningsAccumulatedLosses2024-04-30SC333815ns5:RetainedEarningsAccumulatedLosses2023-04-30SC333815ns5:NetGoodwill2023-05-012024-04-30SC333815ns5:IntangibleAssetsOtherThanGoodwill2023-05-012024-04-30SC333815ns5:HirePurchaseContractsns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-04-30SC333815ns5:HirePurchaseContractsns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-04-30SC333815ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2024-04-30SC333815ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2023-04-30SC333815ns5:HirePurchaseContracts2024-04-30SC333815ns5:HirePurchaseContracts2023-04-30SC333815ns5:WithinOneYear2024-04-30SC333815ns5:WithinOneYear2023-04-30SC333815ns5:BetweenOneFiveYears2024-04-30SC333815ns5:BetweenOneFiveYears2023-04-30SC333815ns5:AllPeriods2024-04-30SC333815ns5:AllPeriods2023-04-30SC333815ns5:Secured2024-04-30SC333815ns5:Secured2023-04-30
REGISTERED NUMBER: SC333815 (Scotland)















Financial Statements For The Year Ended 30 April 2024

for

CMAM Pharmacy Limited

CMAM Pharmacy Limited (Registered number: SC333815)






Contents of the Financial Statements
For The Year Ended 30 April 2024




Page

Company Information 1

Abridged Statement of Financial Position 2

Notes to the Financial Statements 4


CMAM Pharmacy Limited

Company Information
For The Year Ended 30 April 2024







DIRECTORS: Mrs C Henry
Mrs A Duffy





REGISTERED OFFICE: C/o Robb Ferguson
Regent Court
70 West Regent Street
Glasgow
G2 2QZ





REGISTERED NUMBER: SC333815 (Scotland)





ACCOUNTANTS: Robb Ferguson Chartered Accountants
Regent Court
70 West Regent Street
Glasgow
G2 2QZ

CMAM Pharmacy Limited (Registered number: SC333815)

Abridged Statement of Financial Position
30 April 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 608,125 677,625
Tangible assets 5 28,559 20,022
636,684 697,647

CURRENT ASSETS
Stocks 91,977 93,377
Debtors 253,896 251,504
Cash at bank and in hand 432,939 452,510
778,812 797,391
CREDITORS
Amounts falling due within one year 649,447 634,572
NET CURRENT ASSETS 129,365 162,819
TOTAL ASSETS LESS CURRENT
LIABILITIES

766,049

860,466

CREDITORS
Amounts falling due after more than one
year

6

(274,265

)

(390,523

)

PROVISIONS FOR LIABILITIES (1,452 ) -
NET ASSETS 490,332 469,943

CAPITAL AND RESERVES
Called up share capital 2,000 2,000
Retained earnings 488,332 467,943
SHAREHOLDERS' FUNDS 490,332 469,943

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

CMAM Pharmacy Limited (Registered number: SC333815)

Abridged Statement of Financial Position - continued
30 April 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Statement of Comprehensive Income and an abridged Statement of Financial Position for the year ended 30 April 2024 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Statement of Comprehensive Income has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27 August 2024 and were signed on its behalf by:





Mrs C Henry - Director


CMAM Pharmacy Limited (Registered number: SC333815)

Notes to the Financial Statements
For The Year Ended 30 April 2024

1. STATUTORY INFORMATION

CMAM Pharmacy Limited is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover is stated net of VAT and trade discounts. Turnover from the sale of goods is recognised when the goods are physically delivered to the customer. Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the value of the consideration due.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business, is being amortised evenly over its estimated useful life of twenty years. The directors are of the view that 20 years is the appropriate time frame for which to amortise the goodwill. The directors are of this view given the sector that the company operates in, where there is a ready market place for businesses like the one owned by the Company to be traded and where values have historically been resilient.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is shorter.

Leasehold Properties - 5% on cost
Fixed Plant & Equipment - 33.33% on cost and 20% on reducing balance
Computer Equipment - 33.33% on cost
Motor Vehicles - 25% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments
Basic financial instruments are recognised at amortised cost, except for investments in non-convertible preference and non-puttable ordinary shares which are measured at fair value, with changes recognised in the statement of comprehensive income. Derivative financial instruments are initially recorded at cost and thereafter at fair value with changes recognised in the statement of comprehensive income.


CMAM Pharmacy Limited (Registered number: SC333815)

Notes to the Financial Statements - continued
For The Year Ended 30 April 2024

2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial positionstatement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Assets obtained under hire purchase contracts or finance leases are capitalised in the statement of financial position. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to the statement of comprehensive income over the relevant period. The capital element of the future payments is treated as a liability.

Rentals paid under operating leases are charged to the statement of comprehensive income on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 17 (2023 - 18 ) .

CMAM Pharmacy Limited (Registered number: SC333815)

Notes to the Financial Statements - continued
For The Year Ended 30 April 2024

4. INTANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 May 2023
and 30 April 2024 1,390,000
AMORTISATION
At 1 May 2023 712,375
Amortisation for year 69,500
At 30 April 2024 781,875
NET BOOK VALUE

At 30 April 2024 608,125
At 30 April 2023 677,625

5. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 May 2023 113,088
Additions 19,449
Disposals (8,900 )
At 30 April 2024 123,637
DEPRECIATION
At 1 May 2023 93,066
Charge for year 8,800
Eliminated on disposal (6,788 )
At 30 April 2024 95,078
NET BOOK VALUE
At 30 April 2024 28,559
At 30 April 2023 20,022

CMAM Pharmacy Limited (Registered number: SC333815)

Notes to the Financial Statements - continued
For The Year Ended 30 April 2024

5. TANGIBLE FIXED ASSETS - continued

Fixed assets, included in the above, which are held under hire purchase contracts are as follows:

Totals
£   
COST
At 1 May 2023 8,900
Additions 17,983
Disposals (8,900 )
At 30 April 2024 17,983
DEPRECIATION
At 1 May 2023 6,788
Charge for year 4,496
Eliminated on disposal (6,788 )
At 30 April 2024 4,496
NET BOOK VALUE
At 30 April 2024 13,487
At 30 April 2023 2,112

6. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN FIVE
YEARS
2024 2023
£    £   

Repayable by instalments
Bank loans more 5 yr by instal 5,648 11,204

7. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Hire purchase contracts
2024 2023
£    £   
Net obligations repayable:
Within one year 3,597 297
Between one and five years 14,388 -
17,985 297

Non-cancellable operating leases
2024 2023
£    £   
Within one year 44,860 44,860
Between one and five years 61,407 106,267
106,267 151,127

CMAM Pharmacy Limited (Registered number: SC333815)

Notes to the Financial Statements - continued
For The Year Ended 30 April 2024

8. SECURED DEBTS

The following secured debts are included within creditors:

2024 2023
£    £   
Bank loans 390,522 516,701
Hire purchase contracts 17,985 297
408,507 516,998

The Alliance & Leicester plc & Santander UK plc hold bonds and floating charges over all of the assets and undertakings of CMAM Pharmacy Ltd.

9. ULTIMATE CONTROLLING PARTY

The company's ultimate parent company is CMAM Limited, a company incorporated in the UK.